Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million. What happened According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (NASDAQ:PTGX), selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million. What else to know BVF sold out of Protagonist Therapeutics. Top holdings after the filing: NASD ...

Company Overview - Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was founded on August 22, 2006, and is headquartered in Newark, California. The company focuses on developing peptide-based therapies targeting rare diseases, hematology, and immunology [4]. Recent Developments - H.C. Wainwright raised its price target on Protagonist Therapeutics to $117 from $80, reiterating a Buy rating based on the company's drug development track record and probability-of-success assumptions across multiple programs, including PN-8047 and obesity assets [1]. - A company director sold 20,000 shares valued at approximately $1.7 million, an event that investors are monitoring alongside ongoing pipeline developments [3]. - Protagonist Therapeutics reported two potential late-stage assets, Icotrokinra and Rusfertide, with New Drug Applications (NDAs) submitted for plaque psoriasis and polycythemia vera expected in 2025 [3]. Pipeline and Partnerships - The company anticipates multiple Phase 2 and Phase 3 readouts across immunology, hematology, and obesity indications [3]. - Existing partnerships with Johnson & Johnson and Takeda include milestone and royalty structures that support non-dilutive funding [3].

Market Overview - The market in 2025 was characterized by extreme volatility, with small caps experiencing a significant rally followed by a sharp retreat due to various uncertainties, including government policy and AI-related concerns [4][5] - Small caps outperformed large caps in earnings growth for the first time in over a decade during the third quarter, indicating an improving earnings backdrop for this asset class [5][6] - Despite challenges, the U.S. economy showed solid growth, allowing the Federal Reserve to continue its rate-cutting cycle [4] Performance Overview - The ClearBridge Small Cap Growth Strategy underperformed the Russell 2000 Growth Index in the fourth quarter, primarily due to disappointing earnings in the IT sector and a strong rally in biotechnology stocks [6][7] - The biotechnology sector saw a significant rebound, with the Russell 2000 Growth Biotech Index returning 28.1%, highlighting the challenges faced by other sectors [6] - The health care sector contributed positively to performance, with notable individual performers like Penumbra and Insmed [8][19] Portfolio Positioning - In 2025, the company established 29 new investments and exited 19 positions, indicating an active year for idea generation [10][11] - New investments included Protagonist Therapeutics, Simpson Manufacturing Company, BETA Technologies, and Dyne Therapeutics, each with strong growth potential in their respective fields [11][22] - The company maintained a disciplined approach to selling positions where fundamentals changed or catalysts were lacking [10] Outlook - The outlook for small cap growth stocks in 2026 is optimistic, with expectations for a broadening of growth leadership across various industries [13][14] - The productivity benefits of AI are anticipated to become more visible, potentially benefiting companies leveraging AI for efficiency and new product offerings [14] - Capital markets are showing signs of improvement, with increased IPO activity and M&A volumes, creating a favorable environment for small cap investments [15][16]

Core Insights - Protagonist Therapeutics, Inc. announced a leadership change with Dinesh V. Patel, Ph.D. taking on a significant role [1] Company Overview - Protagonist Therapeutics is focused on developing novel therapeutics for various diseases, indicating a commitment to innovation in the biopharmaceutical sector [1]

Core Insights - Protagonist Therapeutics and Takeda announced new 52-week results from the Phase 3 VERIFY study, highlighting the efficacy and safety of rusfertide in treating polycythemia vera (PV) patients, with 61.9% of patients maintaining absence of phlebotomy eligibility from baseline to Week 52 [1][2] Efficacy and Safety - The 52-week data demonstrated sustained efficacy of rusfertide, significantly reducing the need for phlebotomy while maintaining hematocrit control [2] - 61.9% of patients treated with rusfertide maintained a durable clinical response, defined as absence of phlebotomy eligibility [4] - 84.1% of patients who had a clinical response in the Part 1a assessment maintained their response [4] - The median time to first phlebotomy was not reached in the rusfertide group, indicating effective treatment [4] Patient Outcomes - Patients treated with rusfertide reported improvements in quality of life, as measured by PROMIS Fatigue SF-8 and MFSAF TSS [4] - The mean hematocrit remained below 43% through Week 52 for patients treated with rusfertide [4] - Serious adverse events occurred in 8.1% of rusfertide-treated patients, indicating a generally well-tolerated safety profile [5] Long-term Study Insights - The THRIVE study showed a greater than 13-fold reduction in the estimated annual therapeutic phlebotomy rate compared to baseline, with a mean annualized phlebotomy rate dropping from 9.2 to 0.7 phlebotomies/year [6] - The THRIVE study is designed to assess the long-term durability of response and safety profile of rusfertide over an additional two-year treatment period [10] Regulatory and Development Status - Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA, indicating its potential as a significant treatment option for PV [7] - The Phase 3 VERIFY study is ongoing, evaluating rusfertide in 293 patients over a 156-week period [8]

Core Viewpoint - Bolt Biotherapeutics, Inc. (BOLT) is anticipated to report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $5.07 per share, reflecting a year-over-year change of +36.6%, while revenues are projected to be $0.77 million, down 32.5% from the previous year [3]. - The consensus EPS estimate has been revised 0.83% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Bolt Biotherapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.33%, suggesting a bullish outlook on earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Bolt Biotherapeutics was expected to post a loss of $6.4 per share but actually reported a loss of -$4.46, achieving a surprise of +30.31% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Protagonist Therapeutics (PTGX) is expected to report a loss of $0.59 per share for the same quarter, with a year-over-year change of -9.3% and projected revenues of $10 million, up 113.7% from the previous year [18][19]. - Protagonist Therapeutics has a higher Most Accurate Estimate leading to an Earnings ESP of +29.92%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].

Core Insights - Kymera Therapeutics reported a quarterly loss of $0.9 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, marking a surprise of -26.76% [1] - The company's revenues for the quarter ended September 2025 were $2.76 million, missing the Zacks Consensus Estimate by 89.6%, and down from $3.74 million a year ago [2] - The stock has increased approximately 48.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $20.64 million, and for the current fiscal year, it is -$3.28 on revenues of $80.83 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kymera's stock performance [5][6]

Core Insights - MiMedx Group, Inc. is a leader in the advanced wound care and therapeutic biologics sector, focusing on products derived from human placental tissue for medical applications [1] - The company demonstrates impressive financial performance, particularly in its Return on Invested Capital (ROIC) compared to its Weighted Average Cost of Capital (WACC) [1] Financial Performance - MiMedx's ROIC stands at 19.52%, significantly higher than its WACC of 11.70%, resulting in a ROIC to WACC ratio of 1.67, indicating efficient capital utilization [2] - Compared to peers, MiMedx's financial metrics are superior, with AxoGen, Inc. showing a ROIC of 2.07% and a WACC of 8.82%, leading to a ROIC to WACC ratio of 0.23 [3] - MacroGenics, Inc. has a negative ROIC of -37.98% and a WACC of 9.17%, resulting in a ROIC to WACC ratio of -4.14, indicating inefficiency in capital utilization [3] - Enanta Pharmaceuticals, Inc. has a ROIC of -32.77% and a WACC of 6.26%, leading to a ROIC to WACC ratio of -5.23, while Protagonist Therapeutics, Inc. has a ROIC of 3.39% and a WACC of 14.08%, with a ROIC to WACC ratio of 0.24 [4] - Omeros Corporation shows the most concerning figures with a ROIC of -100.12% and a WACC of 11.87%, resulting in a ROIC to WACC ratio of -8.44, highlighting significant inefficiency [5] - MiMedx's strong ROIC to WACC ratio of 1.67 underscores its effective use of invested capital, making it an attractive option for investors [5]

Core Insights - Protagonist Therapeutics, Inc. announced that clinical data on rusfertide in polycythemia vera will be presented at the 67th Annual American Society of Hematology (ASH) Annual Meeting [1] Presentation Details - The focus will be on the Phase 3 VERIFY study, which evaluates rusfertide compared to placebo plus current standard-of-care therapy for polycythemia vera [1] - The presenting author will be Dr. Andrew Kuykendall from Moffitt Cancer Center, with publication number 81 [1] - The oral session will be titled "Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study" [1]

Core Insights - Regeneron reported quarterly earnings of $11.83 per share, exceeding the Zacks Consensus Estimate of $9.44 per share, but down from $12.46 per share a year ago, resulting in an earnings surprise of +25.32% [1] - The company achieved revenues of $3.75 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.38% and showing a slight increase from $3.72 billion year-over-year [2] - Regeneron has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The future performance of Regeneron shares will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $9.35 on revenues of $3.67 billion, while for the current fiscal year, the estimate is $40.08 on revenues of $13.95 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Regeneron belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]